XMD8-92 Inhibits Pancreatic Tumor Xenograft Growth via DCLK1-Dependent Mechanism
Scientists showed that XMD8-92 inhibits AsPC-1 cancer cell proliferation and tumor xenograft growth. XMD8-92 treated tumors demonstrated significant downregulation of doublecortin-like kinase1 (DCLK1) and several of its downstream targets via upregulation of tumor suppressor miRNAs. [Cancer Lett]
Abstract
Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.
SCIENCE NEWS
FibroGen Announces Results of Phase II Study of FG-3019 Indicating Positive Activity against Pancreatic Cancer
FibroGen, Inc. announced results from a Phase II open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. [Press release from FibroGen, Inc. discussing research to be presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago]
Press Release
Post-Hoc Analysis of Overall Survival in Phase III MPACT Study of Patients with Advanced Pancreatic Cancer Presented
Celgene Corporation announced updated overall survival results from a post-hoc analysis of its Phase III MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study of ABRAXANE® in combination with gemcitabine in treatment-naïve patients with metastatic pancreatic cancer. [Press release from Business Wire discussing research presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release
Results of Phase I Study of DMOT4039A, an Antibody-Drug Conjugate, in Patients with Pancreatic or Ovarian Cancer
Researchers describe the results of a Phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian cancers. In this early clinical trial with the goal of identifying possible risks and defining likely dosages, the drug was well tolerated and in some patients showed initial evidence of anti-cancer activity. [Press release from University of Colorado Cancer Center discussing research presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago]
Press Release
Salk Professor Named Grantee in New Pancreatic Cancer Research Program
Ronald M. Evans, director of the Gene Expression Laboratory at Salk and Howard Hughes Medical Institute investigator, is one of three scientists chosen to receive $5 million in research funding as part of The Lustgarten Foundation’s new “Distinguished Scholars” program, which recognizes individuals who have made outstanding achievements in research to focus their efforts on finding a cure for pancreatic cancer. [The Salk Institute for Biological Studies]
Press Release
Recruit Top Talent: Reach more than 50,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!
Comments or Suggestions? Submit your feedback here.